These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19715405)

  • 1. Trimetazidine: the future of cardiac function?
    Di Napoli P; Taccardi AA
    Future Cardiol; 2009 Sep; 5(5):421-4. PubMed ID: 19715405
    [No Abstract]   [Full Text] [Related]  

  • 2. Metabolic approach to heart failure - evidence that trimetazidine improves symptoms, left ventricular function and possibly prognosis.
    Jackson G
    Int J Clin Pract; 2006 Aug; 60(8):891-2. PubMed ID: 16893429
    [No Abstract]   [Full Text] [Related]  

  • 3. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure.
    Gao D; Ning N; Niu X; Hao G; Meng Z
    Heart; 2011 Feb; 97(4):278-86. PubMed ID: 21134903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure.
    Fragasso G; Perseghin G; De Cobelli F; Esposito A; Palloshi A; Lattuada G; Scifo P; Calori G; Del Maschio A; Margonato A
    Eur Heart J; 2006 Apr; 27(8):942-8. PubMed ID: 16510466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic modulation as a target for heart failure treatment: current perspective.
    Chenniapan S; Manchanda SC
    Indian Heart J; 2007; 59(4):370-4. PubMed ID: 19126947
    [No Abstract]   [Full Text] [Related]  

  • 6. Metabolic therapy for heart failure.
    Essop MF; Opie LH
    Eur Heart J; 2004 Oct; 25(20):1765-8. PubMed ID: 15474689
    [No Abstract]   [Full Text] [Related]  

  • 7. Metabolic modulation in heart failure: high time for a definitive clinical trial.
    Ashrafian H; Neubauer S
    Heart; 2011 Feb; 97(4):267-8. PubMed ID: 21258118
    [No Abstract]   [Full Text] [Related]  

  • 8. Trimetazidine and cardioprotection: facts and perspectives.
    Tsioufis K; Andrikopoulos G; Manolis A
    Angiology; 2015 Mar; 66(3):204-10. PubMed ID: 24719262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Trimetazidine in the Treatment of Chronic HeartFailure].
    Zhirov IV; Osmolovskaya YF; Tereshchenko SN
    Kardiologiia; 2016 Jan; 56(1):79-85. PubMed ID: 28294737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of trimetazidine on serum oxygen free radicals in congestive heart failure].
    Ma QL; Xie Y; Zhang SD
    Hunan Yi Ke Da Xue Xue Bao; 2002 Dec; 27(6):527-9. PubMed ID: 12658930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A clinical experience of taurine and trimetazidine use in premenopausal women with chronic heart failure].
    Sedova EM; Magnitskaia OV
    Kardiologiia; 2010; 50(1):62-3. PubMed ID: 20144159
    [No Abstract]   [Full Text] [Related]  

  • 12. Myocardial metabolic manipulation: a new therapeutic approach in heart failure?
    O'Meara E; McMurray JJ
    Heart; 2005 Feb; 91(2):131-2. PubMed ID: 15657211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of heart failure in rats by trimetazidine treatment: a consequence of accelerated phospholipid turnover?
    Tabbi-Anneni I; Helies-Toussaint C; Morin D; Bescond-Jacquet A; Lucien A; Grynberg A
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1003-9. PubMed ID: 12604675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Potentialities of cytoprotection in the treatment of chronic heart failure in patients with coronary heart disease].
    Fedorova TA; Il'ina IuV; Sotnikova TI; Rybakova MK
    Klin Med (Mosk); 2004; 82(11):15-20. PubMed ID: 15656392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can metabolic manipulation reverse myocardial dysfunction?
    Cokkinos DV
    Eur Heart J; 2001 Dec; 22(23):2138-9. PubMed ID: 11913472
    [No Abstract]   [Full Text] [Related]  

  • 16. [Anti-ischemic effects of trimetazidine in patients with post-infarction heart failure].
    Tepliakov AT; Sankevich qV; Stepacheva TA; Garganeeva AA; Filippov EA; Pushnikova EIu; Kaliuzhin VV; Efimova I; Zavadovskiĭ KV
    Klin Med (Mosk); 2004; 82(5):57-62. PubMed ID: 15230045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy.
    Scheuer J
    Circulation; 2009 Mar; 119(11):e371; author reply e372. PubMed ID: 19307483
    [No Abstract]   [Full Text] [Related]  

  • 18. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure.
    Fragasso G; Palloshi A; Puccetti P; Silipigni C; Rossodivita A; Pala M; Calori G; Alfieri O; Margonato A
    J Am Coll Cardiol; 2006 Sep; 48(5):992-8. PubMed ID: 16949492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic approach in heart failure: rethinking how we translate from theory to clinical practice.
    Tang WH
    J Am Coll Cardiol; 2006 Sep; 48(5):999-1000. PubMed ID: 16949493
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic relevance of metabolic approach in patients with heart failure.
    Di Napoli P; Barsotti A
    Curr Pharm Des; 2009; 15(8):883-92. PubMed ID: 19275652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.